Derek Yung
Analyst · Dave Styblo from Jefferies. Your line is now open
Thanks, Scott, and good afternoon, everyone. On today’s call, I will go over our fourth quarter financial results in greater detail, provide our 2021 annual guidance and assess the key drivers behind our 2021 projections. We expect the impact of the operational enhancements outlined by Scott will translate into meaningful improvements in on Medicare unit counts this year, allowing us to drive high quality Medicare enrollment growth, while increasing our profitability. Throughout today’s presentation, I will be making references to our fourth quarter and full year 2020 growth rates relative to 2019. As a reminder, in the fourth quarter of 2019, we worked with an external corporate valuation consultant to increase the accuracy of our Medicare Advantage lifetime value estimates with an emphasis on improving our member retention forecasting by incorporating statistical tools. As a result of enhancements to our LTV model, in Q4 of 2019 we booked a $42.3 million positive revenue impact from a change in estimate for expected cash commission collections for Medicare Advantage plans since we began selling these products and through the third quarter of 2019. For the purposes of year-over-year comparisons in my remarks today, I will be excluding this $42.3 million in revenue from our 2019 results. Fourth quarter 2020 Medicare segment revenue was $269.9 million or 12% year-over-year growth excluding the $42.3 million in Q4 of 2019 related to the enhancement of our Medicare Advantage lifetime value model. Full year 2020 Medicare revenue was $516.8 million, an increase of 28% compared to a year ago, excluding the $42.3 million in 2019. Medicare revenue growth was driven primarily by an increase in approved Medicare Advantage members of 30% and 39% for the fourth quarter and full year 2020, respectively. It also reflects an increase in non-commissioned revenue. In particular, revenue generated from our Medicare Plan Advertising program. Total non-commission revenue grew 99% in the fourth quarter and 89% for the full year 2020 compared to 2019. Strong growth in approved MA members was offset by declines in our constrained lifetime values or LTVs. LTVs in our Medicare Advantage business declined 10% in the fourth quarter and 6% for the full year 2020 compared to a year ago, which is consistent with our expectations and it is reflective primarily of increased churn levels that were reported earlier last year. As a reminder, pursuant to ASC 606 revenue accounting, we are estimating in-period lifetime values based on historical churn observations. For 2021 guidance discussion later on the call, I will share our LTV projections for 2021, which will reflect the positive impact expected from the retention activities that we put in place, as well as an increase in broker commissions rates this year. The number of approved Medicare Supplement and Prescription Drug Plan members declined in the fourth quarter and full year 2020 compared to a year ago. In the Medicare Supplement business, this was primarily driven by our decision to shift marketing and call center resources towards the MA product, which continues to gain popularity among seniors as the quality, selection and affordability of these plans have continued to increase. The decline in approved PDP members was driven by lower PDP volumes from our pharmacy partner channel, compared to a year ago, combined with a reduced demand for standalone PDP plans compared to Medicare Advantage products was built in prescription drug cost coverage known as MAPDs. For the fourth quarter of 2020, the Medicare segment generated a profit of $82.6 million. This compares to $107 million in the fourth quarter of 2019, excluding the impact of the $42.3 million in q4 of 2019, related to the enhancement of our Medicare Advantage LTV model. For the full year of 2020, Medicare segment profit was $102 million, compared to the $112.9 million in 2019, excluding the $42.3 million. The year over year reduction in Medicare segment profit was driven primarily by the underperformance of our vendor agents and suffered unexpected consumer demand in certain marketing channels during the AEP. I will go into more detail during my review of the fourth quarter operating expenses later on the call. The estimated number of commission’s generating Medicare members was approximately 876,000 at the end of 2021, an increase of 23% compared to 2019, reflecting growth that was well ahead of the overall Medicare enrollment growth as reported by CMS. Our estimated Medicare Advantage membership of 533,000 grew 32%, also significantly ahead of the overall Medicare Advantage enrollment growth in the United States. The trailing 12-month churn rate in our Medicare Advantage business that we calculate based on our estimated membership and new paying members was 40%, an improvement compared to the 42% we reported in Q3 and in line with our expectations. Please note that our estimated fourth quarter TTM churn still reflects the elevated churn rates that we observed and previously reported early in 2020. When we report first quarter results in April, we expect that we would be able to show the initial impact of our retention efforts implemented last year. We expect that MA members that were enrolled during the last AEP in Q4 of 2020 will churn at lower rates in their first year compared to the AEP cohort from 2019. Year one of enrollment is a critical period from a retention standpoint, because it has historically been the highest churn during any annual period in a policy life. While we’ll have some data on churn when we report Q1 results, given a time lag about data about churn, we’ll have a more comprehensive view later in the year as we learn more about the impact of the Medicare open enrollment period that takes place during Q1 and offers MA members another opportunity to switch plans. Fourth quarter 2020 revenue from our individual, family and small business segments was $23.4 million, a 22% increase compared to a year ago. Full year of 2020 revenue in this segment was $66 million, an 11% increase compared to 2019. Revenue growth was driven primarily by residual or tail revenue from our existing members on individual and family and ancillary plans. We continue to see increased member retention in this business, in particular for subsidy eligible ACA plans and short-term products. Commission revenue from our small business group products declined 23% in the fourth quarter and 4% for the full year 2020 compared to a year ago, as we continue to focus our investments in a Medicare business. The individual, family and small business segment remain profitable on a standalone basis, generating segment profit of $15.9 million for the fourth quarter and $39.4 million for the full year of 2020. Our estimated individual and family plan membership at the end of the fourth quarter was approximately 116,200, down 10% compared to the estimated membership we reported at the end of fourth quarter a year ago. The estimated number of members on small business products was approximately 45,800 and at end of the year, a 7% increase compared to a year ago. Total revenue for the fourth quarter was $293.3 million or a 13% year-over-year growth excluding the $42.3 million in Q4 2019. Revenue for the full year 2020 was $582.8 million, a 20% -- 26% increase, excluding the impact of the $42.3 million in 2019. Now I’ll review our operating expenses and profitability metrics. Our plan for 2020 was to build on two consecutive years of improving EBITDA profitability achieved in 2018 and 2019. We targeted EBITDA margin expansion through fixed cost leverage and lower agent costs per approved Medicare member and plan to conduct more of our enrollments online. While we slow down our fixed cost growth in 2020 relative to 2019 and successfully increased the percentage of fully unassisted online enrollments, the positive impact from these factors was offset by underperformance of our vendor agents and overall Medicare enrollment shortfall. During the fourth quarter, our vendor agents converted demand at lower rates relative our expectations and to 2019 levels. Combined with higher lead costs in the Direct TV channel, that we observed this AEP, this resulted in unfavorable per member acquisition costs in our Medicare business. In addition, we made investments ahead of the AEP to prepare for the larger enrollment volumes that we anticipated, including prepaid marketing campaigns and vendor agent capacity expansion, which involves a meaningful upfront investment. Total variable acquisition costs per approved Medicare member grew 23% in the fourth quarter of 2020 compared to Q4 of 2019, with customer care enrollment costs growing 18% and marketing costs growing 26% over the same time period. After we terminated the underperforming vendor agents during the quarter, our overall call center productivity metrics rapidly improved, but not enough to fully mitigate the impact of the vendor agent underperformance on a per member acquisition costs. On a fixed cost side, our fourth quarter non-GAAP technology and content costs, which exclude stock-based compensation, acquisition costs, restructuring charge and amortization of intangibles increased by 14% compared to Q4 2019. Non-GAAP general and administrative costs declined by 2% over the same time periods. Fourth quarter 2020 adjusted EBITDA was at $4.2 million, representing a 29% EBITDA margin, compared to $100.3 million or 39% EBITDA margin in the fourth quarter of 2019, excluding the $42.3 million. Adjusted EBITDA for the full year 2020 was $83.7 million or 14% margin. This compares to $90.9 million or 20% margin, excluding the impact of the $42.3 million positive revenue impact in 2019. Please refer to our fourth quarter and fiscal year 2020 earnings released for a description of how we calculate adjusted EBITDA. GAAP net income was $59.9 million for the fourth quarter of 2020 and $45.5 million for the full year 2020. Our fourth quarter 2020 cash flow from operations was negative $96.9 million, compared to a negative $56.8 million for the fourth quarter of 2019. For the full year, cash flow from of operations was negative $107.9 million. Capital expenditures, which include capitalized internally developed software costs were approximately $23.8 million for the full year. Our cash, cash equivalents and marketable securities were $93.4 million as of December 31, 2020 with no debt. We ended the year with a commission’s receivable balance of $792 million. And now, I’ll provide our 2021 annual guidance. Please note that this guidance excludes potentially impact from our transaction with HIG Capital pending its closing. We’re forecasting revenue for 2021 to be in the range of $660 million to $700 million, with Medicare segment revenue in the range of $621 million to $690 -- $659 million, and individual, family and small business segment revenue in the range of $39 million to $41 million. We expect GAAP net income for 2021 to be in the range of $42 million to 57 million. We expect 2021 adjusted EBITDA to be in the range of $100 million to $115 million. 2021 Medicare segment profit is expected to be in the range of $138 million to $155 million, and individual, family and small business segment profits is expected to be in a range of $18 million to $19 million. Corporate shared service expenses, excluding stock-based compensation and depreciation amortization expense is expected to be in a range of $56 million to $59 million. GAAP net income per diluted share for 2021 is expected to be in the range of $1.53 per share to $2.08 per share. Non GAAP net income per diluted share for 2021 is expected to be in the range of $2.77 per share to $3.26 per share. Cash used in operations is expected in the range of $85 million to $95 million and cash use for capital expenditures expected to be in the range of $24 million to $27 million. The midpoint of our 2021 guidance implies 17% total revenue growth, with roughly 24% Medicare revenue growth compared to 2020. Medicare enrollment growth is expected to be the main driver of revenue growth this year with approved members for all Medicare products expected to grow in the low 20s and Medicare Advantage enrollment in the high 20s compared to last year. Medicare enrollment growth is expected to be accompanied by an expansion of our Medicare Advantage lifetime values, which we forecast to increase approximately 6.5% for the full year 2021 compared to 2020. At the same time, we currently projected our non-commission revenue will be roughly flat with 2020 levels after growing close to 90% last year. In addition, we expect to see a decline in our tail or residual revenue in 2021. After booking around $38 million in net tail revenue into aggregate across our Medicare, IFP and ancillary products in 2020, we’re currently forecast to have little to no tail revenue in these areas in ‘21. Based on a midpoint of our adjusted EBITDA guidance, we expect to generate a margin of roughly 16% compared to our 2020 adjusted EBITDA margin of 14%. This margin expansion is expected to be a driver primarily by fixed cost leverage and a reduction in per member acquisition costs in our Medicare business as a result of improved productivity of our agent force and to a lesser extent due to changes in our marketing mix with decreased reliance on DR TV and increased contribution from fully unassisted online enrollment to our total Medicare applications. The forecasted reduction in our per member acquisition costs, combined with an increase Medicare Advantage LTVs is expected to deliver a meaningful expansion in our Medicare member economics for the full year 2021 compared to 2020. The positive impact of these factors on our EBITDA margins will be partially offset by year-over-year decline in higher margin revenue items including non-commission revenue and residual revenue. I would also like to make some comments with respect to the seasonality that we expect to this year. The fourth quarter will continue to contribute disproportionally to revenue and earnings driven by the timing of the Medicare annual enrollment period and ACA open enrollment period selling season. In fact, we expect a fourth quarter will drive the vast majority of our revenue and EBITDA growth in 2021 compared to 2021. In terms of quarterly cadence of our Medicare Advantage LTVs, we’re currently forecast for LTV to be down year-over-year in the first and second quarters of 2021, reflecting the impact of churn in the first half of last year, prior to the deployment of our retention program. We projected that LTVs will start increasing in Q3 compared to Q3 2019, with the largest year-over-year increase of 10% or better expected in the fourth quarter, driven primarily by what we believe was a significant increase in quality of MA enrollments in Q4 of 2020. So while we expect to see strong member growth in the first quarter, it will be offset by lower LTVs and lower tail revenue, resulting in total revenue growth in a low-single digits compared to Q1 2020. We also expect first quarter adjusted EBITDA to be down compared to the first quarter 2020 also due to lower LTVs and lower tail revenue. Finally, with respect to our online strategy, we expect the online enrollment will represent 43% of our total 2021 Medicare major medical enrollment, compared to 37% in 2020. I want to remind you that these comments and our guidance are based on current indications for our business and our current estimates assumptions and judgments, which may change at any time. While actual results may differ as a result of changes in our estimates, assumptions and judgments, we undertake no obligation to update our comments or our guidance. With that, I’ll turn the call over back to the operator for Q&A.